نتائج البحث - "Philipp Le Coutre"

1

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

المؤلفون: Arlene Reisman, Bfore Study Investigators, Valentín García-Gutiérrez, Charles Chuah, Carlo Gambacorti-Passerini, Andreas Hochhaus, Michael W. Deininger, Dragana Milojkovic, Rocco J. Crescenzo, Tim H. Brümmendorf, Philipp le Coutre, Carla Mamolo, Jorge E. Cortes, Dong-Wook Kim, Michael J. Mauro

المساهمون: Cortes, J, Gambacorti-Passerini, C, Deininger, M, Mauro, M, Chuah, C, Kim, D, Milojkovic, D, le Coutre, P, Garcia-Gutierrez, V, Crescenzo, R, Mamolo, C, Reisman, A, Hochhaus, A, Brummendorf, T

المصدر: Journal of cancer research and clinical oncology. 145(6)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Health-related quality of life, Population, Newly diagnosed, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Quality of life, hemic and lymphatic diseases, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Surveys and Questionnaires, Nitriles, Medicine, Humans, Patient Reported Outcome Measures, education, Patient-reported outcome, education.field_of_study, Hematology, Aniline Compounds, business.industry, Chronic myeloid leukemia, Cancer, Imatinib, General Medicine, Chronic phase chronic myeloid leukemia, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Quality of Life, Quinolines, Bosutinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e16f05ee7c729b1643915c6e699c795Test
https://pubmed.ncbi.nlm.nih.gov/30989330Test

2

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

المساهمون: Cortes, J, Kim, D, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F, Apperley, J, Khoury, H, Talpaz, M, Deangelo, D, Abruzzese, E, Rea, D, Baccarani, M, Müller, M, Gambacorti-Passerini, C, Lustgarten, S, Rivera, V, Haluska, F, Guilhot, F, Deininger, M, Hochhaus, A, Hughes, T, Shah, N, Kantarjian, H

مصطلحات موضوعية: Male, Time Factors, Clinical Trials and Observations, NILOTINIB, Biochemistry, RECOMMENDATIONS, chemistry.chemical_compound, 0302 clinical medicine, MED/15 - MALATTIE DEL SANGUE, hemic and lymphatic diseases, 1114 Paediatrics And Reproductive Medicine, Cumulative incidence, Philadelphia Chromosome, IMATINIB-RESISTANT, BCR-ABL, Philadelphia chromosome positive, Aged, 80 and over, education.field_of_study, DASATINIB, Ponatinib, CHRONIC MYELOGENOUS LEUKEMIA, Imidazoles, Hematology, Middle Aged, Prognosis, Dasatinib, Pyridazines, Survival Rate, 030220 oncology & carcinogenesis, Female, Safety, TYROSINE KINASE INHIBITOR, Life Sciences & Biomedicine, medicine.drug, Adult, medicine.medical_specialty, Population, Immunology, Antineoplastic Agents, acute lymphoblastic leukemia, Philadelphia chromosome, 1102 Cardiovascular Medicine And Haematology, CML PATIENTS, 03 medical and health sciences, Young Adult, chronic myeloid leukemia, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, BCR-ABL INHIBITOR, medicine, Humans, Adverse effect, education, CHRONIC MYELOID-LEUKEMIA, Survival rate, Aged, Salvage Therapy, Science & Technology, business.industry, 1103 Clinical Sciences, Cell Biology, medicine.disease, chemistry, Nilotinib, Drug Resistance, Neoplasm, ADVERSE EVENTS, business, 030215 immunology, Follow-Up Studies